St. Jude Medical is expanding its cardiac resynchronization therapy portfolio with SyncAV CRT software, which just received CE mark approval. The software builds on the company's MultiPoint Pacing tech.
Medtronic has won the first U.S. approval for a leadless pacemaker from the FDA. The inch-long device is the smallest available and is implanted directly into the heart's right ventricle chamber. Traditional pacemakers require wired leads to connect the device to the heart.
Medtronic has launched the first app-based remote monitoring for implantable pacemakers. Remote monitoring of pacemakers has been the standard of care, but this next-gen version goes beyond a dedicated device to do so.
Research presented at a European conference found that wearers of cardiac devices should keep a safe distance from smartphones.
A strategic device company, a former Medtronic president and an award-winning Stanford doctor are among the financiers of Silicon Valley's EBR Systems' attempt to commercialize the first leadless pacemaker implanted in the heart's left ventricle. Along with VCs like Split Rock Partners and SV Life Sciences, the group contributed $20 million toward the groundbreaking effort.
Boston Scientific advised physicians about a particular pacemaker in 2005--but then declined to pay the bills for those surgeries that it subsequently received from German health insurers. An EU court ruled on March 5 that the company is liable for those costs, according to Reuters.
St. Jude Medical has gained approval for a quadripolar cardiac resynchronization therapy pacemaker that for the first time incorporates its MultiPoint Pacing technology that's been shown to be better for patients who don't respond to traditional biventrical pacing.
Boston Scientific owes $309 million in royalties and other expenses to Mirowski Family Ventures, associated with the deceased Dr. Michel Mirowski, principal inventor of the the pacemaker, said a jury in Maryland's Montgomery County Circuit Court yesterday.
Medtronic snagged FDA approval for its next-generation cardiac resynchronization therapy (CRT) pacemaker in patients with heart failure, expanding its cardiovascular portfolio and advancing its proprietary technology for heart rhythm therapy.
Engineering students at Purdue University have come up with what they say is a simple, cost-effective tool cardiac surgeons can use to test whether pacemaker leads have been securely anchored to heart tissue.